The Olfactory Receptor Gene Product, OR5H2, Modulates Endometrial Cancer Cells Proliferation via Interaction with the IGF1 Signaling Pathway.
Animals
Cell Line, Tumor
Cell Proliferation
Cystadenocarcinoma, Serous
/ metabolism
Endometrial Neoplasms
/ metabolism
Female
Gene Expression Regulation, Neoplastic
/ physiology
Humans
Insulin-Like Growth Factor I
/ metabolism
Laron Syndrome
/ genetics
Mice
Mice, Transgenic
Receptor, IGF Type 1
/ metabolism
Receptors, Odorant
/ metabolism
Signal Transduction
/ physiology
IGF1 receptor
Laron syndrome
OR5H2
endometrial cancer
insulin-like growth factor-1 (IGF1)
olfactory receptors
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
12 06 2021
12 06 2021
Historique:
received:
04
05
2021
revised:
08
06
2021
accepted:
08
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
26
10
2021
Statut:
epublish
Résumé
Endometrial cancer is the most common gynecologic malignancy in Western countries. The insulin-like growth factor-1 (IGF1) axis has an important role in endometrial cancer biology and emerged as a promising therapeutic target in oncology. However, there is an urgent need to identify biomarkers that may help in patient stratification and prognosis. Laron syndrome (LS) is a type of dwarfism that results from the mutation of the growth hormone receptor (GHR) gene, leading to congenital IGF1 deficiency. While high circulating IGF1 is regarded as a risk factor in cancer, epidemiological studies have shown that LS patients are protected from cancer development. Recent genome-wide profilings conducted on LS-derived lymphoblastoid cells led to the identification of a series of genes whose over- or under-representation in this condition might be mechanistically linked to cancer protection. The olfactory receptor 5 subfamily H member 2 (
Identifiants
pubmed: 34204736
pii: cells10061483
doi: 10.3390/cells10061483
pmc: PMC8231575
pii:
doi:
Substances chimiques
IGF1 protein, human
0
IGF1R protein, human
0
Receptors, Odorant
0
Insulin-Like Growth Factor I
67763-96-6
Receptor, IGF Type 1
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : United States-Israel Binational Science Foundation
ID : 2013282
Références
Isr J Med Sci. 1966 Mar-Apr;2(2):152-5
pubmed: 5916640
Prostate Cancer Prostatic Dis. 2006;9(1):56-61
pubmed: 16231015
BMC Res Notes. 2017 Oct 30;10(1):541
pubmed: 29084601
Oncotarget. 2020 Apr 28;11(17):1515-1530
pubmed: 32391121
Physiol Rev. 2018 Jul 1;98(3):1739-1763
pubmed: 29897292
Clin Cancer Res. 2008 Apr 15;14(8):2263-9
pubmed: 18369088
Cell Mol Life Sci. 2014 Jul;71(13):2403-27
pubmed: 24276851
Lancet. 1998 May 9;351(9113):1393-6
pubmed: 9593409
Clin Cancer Res. 2016 Jul 1;22(13):3298-309
pubmed: 26861454
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Pediatr Endocrinol Rev. 2008 Feb;5 Suppl 2:739-43
pubmed: 18317445
Br J Cancer. 2006 Mar 13;94(5):642-6
pubmed: 16495918
Endocrinol Metab Clin North Am. 2012 Jun;41(2):231-47, v
pubmed: 22682628
Endocr Relat Cancer. 2016 May;23(5):399-410
pubmed: 27090428
Growth Horm IGF Res. 2014 Aug;24(4):112-8
pubmed: 24863809
Front Endocrinol (Lausanne). 2014 May 19;5:76
pubmed: 24904527
Int J Cancer. 2006 Mar 15;118(6):1471-80
pubmed: 16206286
Cancer Res. 2005 May 1;65(9):3868-76
pubmed: 15867386
Eur J Cancer. 2012 Jul;48(10):1570-80
pubmed: 22033326
J Biol Chem. 2021 Feb 25;:100475
pubmed: 33640452
J Mol Endocrinol. 2013 Nov 07;51(3):277-86
pubmed: 23969981
Growth Horm IGF Res. 2016 Jun;28:6-10
pubmed: 26059750
Regul Pept. 1993 Oct 20;48(1-2):165-77
pubmed: 7505463
Science. 1998 Jan 23;279(5350):563-6
pubmed: 9438850
Endocrinol Metab Clin North Am. 2012 Jun;41(2):249-63, v
pubmed: 22682629
Mol Cell Endocrinol. 2021 Jan 15;520:111075
pubmed: 33181235
J Clin Endocrinol Metab. 2004 Mar;89(3):1031-44
pubmed: 15001582
Cancer Lett. 2013 Jul 10;335(1):153-9
pubmed: 23402816
Cells. 2019 Jun 15;8(6):
pubmed: 31208077
Expert Opin Ther Targets. 2013 Mar;17(3):307-20
pubmed: 23294364
Pediatr Endocrinol Rev. 2018 Sep;16(Suppl 1):39-62
pubmed: 30378782
J Cell Physiol. 2018 Mar;233(3):2104-2115
pubmed: 28338216
Clin Cancer Res. 2016 Jun 15;22(12):2897-907
pubmed: 26831715
Trends Endocrinol Metab. 2008 Aug;19(6):197-205
pubmed: 18515143
Eur J Endocrinol. 2011 Apr;164(4):485-9
pubmed: 21292919
Lancet. 2004 Apr 24;363(9418):1346-53
pubmed: 15110491
Eur J Gynaecol Oncol. 2004;25(2):187-91
pubmed: 15032278
Clin Cancer Res. 2002 May;8(5):1271-9
pubmed: 12006548
Methods Cell Biol. 2016;132:127-45
pubmed: 26928542
Cancer Res. 2004 Jan 1;64(1):236-42
pubmed: 14729630
Sci Transl Med. 2011 Feb 16;3(70):70ra13
pubmed: 21325617
Growth Horm IGF Res. 2007 Feb;17(1):54-7
pubmed: 17166755
Mol Cell Endocrinol. 2020 Dec 1;518:111003
pubmed: 32919021
Sci Rep. 2019 Sep 24;9(1):13736
pubmed: 31551495
N Engl J Med. 1989 Oct 12;321(15):989-95
pubmed: 2779634
Gynecol Oncol. 1994 Sep;54(3):264-8
pubmed: 8088602
Eur J Endocrinol. 2013 Jan 17;168(2):253-61
pubmed: 23184910
Int J Cancer. 2003 Dec 20;107(6):873-7
pubmed: 14601044
Cells. 2020 Nov 09;9(11):
pubmed: 33182502